This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baggish, A. L. Articles by Boucher, C. A. Search for Related Content PubMed PubMed Citation Articles by Baggish, A. L. Articles by Boucher, C. A. Pubmed/NCBI databases Medline Plus Health Information Heart Diseases Nuclear Scans Related Collections Nuclear cardiology and PET

(Circulation. 2008;118:1668-1674.)
© 2008 American Heart Association, Inc.

Contemporary Reviews in Cardiovascular Medicine

Radiopharmaceutical Agents for Myocardial Perfusion Imaging

Aaron L. Baggish, MD; Charles A. Boucher, MD

From the Division of Cardiology, Massachusetts General Hospital, Boston, Mass.

Correspondence to Charles Boucher, MD, Division of Cardiology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114. E-mail cboucher@partners.org

Key Words: isotopes • radioisotopes • myocardial ischemia • nuclear medicine • radiopharmaceuticals

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Myocardial perfusion imaging (MPI) is a well-established noninvasive method of assessing coronary blood flow.^1–5 MPI is capable of identifying regional abnormalities in coronary artery blood flow and determining their physiological relevance to myocardial function and viability. MPI requires the intravenous injection of a radioactive blood flow marker followed by imaging of regional myocardial uptake.^6–10 Imaging is most frequently performed by tomographic techniques (ie, SPECT [single-photon emission computerized tomography]) with electrocardiographically synchronized image gating. Used frequently in conjunction with either physical exercise or pharmacological stress, MPI is useful in unmasking myocardial perfusion deficits not evident at rest. A thorough discussion of clinical indications for MPI is beyond the scope of this review, but the reader is referred to recently published consensus committee documents.^11,12

Three radioactive blood flow markers (RBFMs) are clinically available and in widespread use: (1) thallium Tl 201 chloride, (2) technetium Tc-99m sestamibi (Cardiolite; Lantheus Medical Imaging, North Billerica, Mass), and (3) technetium Tc-99m tetrofosmin (Myoview; GE Healthcare, Princeton, NJ). In the present review, these agents will be referred to by their nonproprietary names. The oldest of the 3 RBFMs, thallium 201, has been in use since approximately 1980, and the original experimental and clinical validation studies of MPI were performed with this agent.^1,13–16 More recently, ^99mTc-labeled sestamibi, approved in 1990, and tetrofosmin, approved in 1995, have been developed and validated clinically.^6–8,17,18

In comparative imaging studies analyzed for accuracy (sensitivity, specificity, and normalcy rates), no obvious differences have been found among these 3 agents. Each RBFM has unique properties . . . [Full Text of this Article]

This article has been cited by other articles:

				M. Salerno and G. A. Beller Noninvasive Assessment of Myocardial Perfusion Circ Cardiovasc Imaging, September 1, 2009; 2(5): 412 - 424. [Full Text] [PDF]